Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | TACR3 | P29371 | 8/20 | 0.38 |
| ▸ | TACR2 | P21452 | 6/20 | 0.38 |
| ▸ | TACR1 | P25103 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935850 | 0.76 | DPP4 (0.48) | DPP4DPP8PARP1PARP2PARP3 | |
| SCHEMBL3840704 | 0.71 | DPP4 (0.91) | DPP4DPP8DPP7 | |
| SCHEMBL24493479 | 0.69 | DPP4 (0.42) | DPP4DPP8PARP1PARP2PARP3 | |
| SCHEMBL3868870 | 0.67 | TACR3 (0.39) | DPP4DPP8PARP1PARP2PARP3 | |
| Hydrochloric Acid SCHEMBL3842582 | 0.66 | TACR3 (0.38) | DPP4DPP8PARP1PARP2PARP3 | |
| SCHEMBL14970386 | 0.66 | DPP4 (0.53) | DPP4DPP8PARP1PARP2PARP3 | |
| SCHEMBL5231477 | 0.65 | TACR3 (0.46) | DPP4DPP8PARP1PARP2PARP3 | |
| SCHEMBL4819589 | 0.64 | DPP4 (0.55) | DPP4DPP8P2RX7DPP7 | |
| SCHEMBL16790052 | 0.63 | DPP4 (0.32) | DPP4DPP8DPP7 | |
| SCHEMBL3135974 | 0.62 | DPP4 (0.55) | DPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624874-B1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7560455-B2 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060258646-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258646-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885PARP1 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.